Total Payments
$40,972
2024 Payments
$8,359
Companies
15
Transactions
73
Payment Breakdown by Category
Research$19,992 (48.8%)
Consulting$19,825 (48.4%)
Food & Beverage$1,155 (2.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19,992 | 19 | 48.8% |
| Consulting Fee | $19,825 | 33 | 48.4% |
| Food and Beverage | $1,155 | 21 | 2.8% |
Payments by Type
General
$20,980
54 transactions
Research
$19,992
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca UK Limited | $17,700 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,963 | 9 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,792 | 6 | $0 (2024) |
| UCB Biosciences Inc. | $2,125 | 2 | $0 (2023) |
| AstraZeneca AB | $1,850 | 3 | $0 (2021) |
| SANOFI US SERVICES INC. | $1,838 | 3 | $0 (2019) |
| Celgene Corporation | $900.00 | 1 | $0 (2019) |
| Eisai Inc. | $500.00 | 1 | $0 (2021) |
| PFIZER INC. | $377.51 | 9 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $264.88 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,359 | 14 | AstraZeneca UK Limited ($6,602) |
| 2023 | $5,950 | 7 | Regeneron Pharmaceuticals, Inc. ($2,125) |
| 2022 | $9,367 | 8 | Novartis Pharmaceuticals Corporation ($5,829) |
| 2021 | $7,625 | 12 | AstraZeneca UK Limited ($3,563) |
| 2020 | $3,713 | 7 | AstraZeneca UK Limited ($1,931) |
| 2019 | $5,100 | 8 | AstraZeneca UK Limited ($2,213) |
| 2018 | $544.49 | 9 | PFIZER INC. ($223.38) |
| 2017 | $314.12 | 8 | PFIZER INC. ($140.47) |
All Payment Transactions
73 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/07/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 11/07/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 09/23/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 08/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| 08/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| 08/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| 08/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $340.00 | General |
| 08/22/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $340.00 | Research |
| Study: A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | ||||||
| 06/20/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $850.00 | Research |
| Study: A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | ||||||
| 03/20/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $567.00 | General |
| 03/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $566.65 | Research |
| Study: A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | ||||||
| 01/11/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 08/03/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $850.00 | Research |
| Study: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | ||||||
| 07/06/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,700.00 | Research |
| Study: A first-in-human, randomized, participant- and investigator-blinded, placebo-controlled, two-part, single ascending intravenous dose study, to assess the safety, tolerability, and pharmacokinetics of VHB937 in healthy non-Japanese and Japanese adults | ||||||
| 06/01/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 06/01/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $850.00 | Research |
| Study: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | ||||||
| 03/23/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $850.00 | General |
| 03/13/2023 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $425.00 | Research |
| Study: A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | ||||||
| 03/13/2023 | UCB Biosciences Inc. | — | — | Cash or cash equivalent | $425.00 | Research |
| Study: A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | ||||||
| 08/22/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $566.67 | General |
| 08/16/2022 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $146.23 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 06/01/2022 | UCB Biosciences Inc. | — | — | Cash or cash equivalent | $1,700.00 | Research |
| Study: A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | ||||||
| 05/12/2022 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $562.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED, TWO-PART, SINGLE ASCENDING INTRAVENOUS DOSE STUDY, TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF VHB937 IN HEALTHY NON-JAPANESE AND JAPANESE ADULTS | Novartis Pharmaceuticals Corporation | $3,950 | 2 |
| A Phase I Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 After Single and Multiple Dosing to Healthy Subjects | AstraZeneca UK Limited | $2,213 | 1 |
| A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND REPEAT-DOSE (PART B, PARTICIPANT-, INVESTIGATOR-, AND SPONSOR-BLIND) STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS, AND EFFICACY (PART B ONLY) OF UCB1381 IN HEALTHY STUDY PARTICIPANTS (PART A) AND IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (PART B) | UCB Biosciences Inc. | $2,125 | 2 |
| A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adult Participants | Regeneron Pharmaceuticals, Inc. | $2,125 | 3 |
| A FIRST-IN-HUMAN, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR-BLINDED, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF XEP527 IN HEALTHY PARTICIPANTS | Novartis Pharmaceuticals Corporation | $1,879 | 1 |
| A RANDOMIZED, PARTICIPANT AND INVESTIGATOR-BLINDED, PLACEBO-CONTROLLED FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF NCJ424 IN HEALTHY ADULT PARTICIPANTS | Novartis Pharmaceuticals Corporation | $1,844 | 2 |
| A first-in-human, randomized, participant- and investigator-blinded, placebo-controlled, two-part, single ascending intravenous dose study, to assess the safety, tolerability, and pharmacokinetics of VHB937 in healthy non-Japanese and Japanese adults | Novartis Pharmaceuticals Corporation | $1,700 | 1 |
| A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | Regeneron Pharmaceuticals, Inc. | $1,417 | 2 |
| A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects with Moderate to Severe Plaque-type Psoriasis (CC-90005-CP-001) | Celgene Corporation | $900.00 | 1 |
| A 3-PART FIRST-IN-HUMAN STUDY CONSISTING OF RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED, SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RHH646, AND A RANDOMIZED, OPEN-LABEL | Novartis Pharmaceuticals Corporation | $750.00 | 1 |
| A 3-PART FIRST-IN-HUMAN STUDY CONSISTING OF RANDOMIZED, DOUBLE-BLINDED, PLACEBOCONTROLLED, SINGLE AND MULTIPLE ASCENDING ORAL DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RHH646, AND A RANDOMIZED, OPEN-LABEL CROSS-OVER STUDY TO INVESTIGATE FOOD EFFECT IN HEALTHY VOLUNTEERS | Novartis Pharmaceuticals Corporation | $500.00 | 1 |
| A first-in-human, randomized, participant and investigator blinded, placebo-controlled, single ascending dose with interleaved cohorts and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of YMI024 in healthy participants | Novartis Pharmaceuticals Corporation | $340.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Volunteers | Regeneron Pharmaceuticals, Inc. | $250.00 | 1 |
About Walter Le
Walter Le is a Internal Medicine healthcare provider based in Whittier, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2014. The National Provider Identifier (NPI) number assigned to this provider is 1174943013.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Walter Le has received a total of $40,972 in payments from pharmaceutical and medical device companies, with $8,359 received in 2024. These payments were reported across 73 transactions from 15 companies. The most common payment nature is "" ($19,992).
Ad
Practice Information
- Specialty Internal Medicine
- Location Whittier, CA
- Active Since 04/18/2014
- Last Updated 08/23/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1174943013
Products in Payments
- BIVV020 (Drug) $1,838
- NCJ424A (Drug) $1,031
- CC-90005 (Drug) $900.00
- ELIQUIS (Drug) $642.39
- LifeVest (Device) $146.23
- Kcentra (Biological) $125.00
- Adempas (Drug) $123.28
- Aimovig (Biological) $117.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Whittier
Jayakumar Vidhun, M.d, M.D
Internal Medicine — Payments: $413,543
Internal Medicine $413,543
Tien I Su, M.d, M.D
Internal Medicine — Payments: $144,568
Internal Medicine $144,568
Mr. Mark Lee, Md, MD
Internal Medicine — Payments: $18,952
Internal Medicine $18,952
Dr. Juan Montes, M.d, M.D
Internal Medicine — Payments: $10,928
Internal Medicine $10,928
Kesheng Wu, Md, MD
Internal Medicine — Payments: $5,355
Internal Medicine $5,355
Kevin Huang, M.d, M.D
Internal Medicine — Payments: $4,437
Internal Medicine $4,437